JP2022519770A5 - - Google Patents

Info

Publication number
JP2022519770A5
JP2022519770A5 JP2021547528A JP2021547528A JP2022519770A5 JP 2022519770 A5 JP2022519770 A5 JP 2022519770A5 JP 2021547528 A JP2021547528 A JP 2021547528A JP 2021547528 A JP2021547528 A JP 2021547528A JP 2022519770 A5 JP2022519770 A5 JP 2022519770A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
cycloalkyl
alkoxy
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021547528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519770A (ja
JP7476216B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018203 external-priority patent/WO2020168143A1/en
Publication of JP2022519770A publication Critical patent/JP2022519770A/ja
Publication of JP2022519770A5 publication Critical patent/JP2022519770A5/ja
Application granted granted Critical
Publication of JP7476216B2 publication Critical patent/JP7476216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547528A 2019-02-15 2020-02-14 ファルネソイドx受容体モジュレータとしての置換二環式化合物 Active JP7476216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806066P 2019-02-15 2019-02-15
US62/806,066 2019-02-15
PCT/US2020/018203 WO2020168143A1 (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators

Publications (3)

Publication Number Publication Date
JP2022519770A JP2022519770A (ja) 2022-03-24
JP2022519770A5 true JP2022519770A5 (cg-RX-API-DMAC7.html) 2022-12-22
JP7476216B2 JP7476216B2 (ja) 2024-04-30

Family

ID=69811921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547528A Active JP7476216B2 (ja) 2019-02-15 2020-02-14 ファルネソイドx受容体モジュレータとしての置換二環式化合物

Country Status (18)

Country Link
US (2) US11254663B2 (cg-RX-API-DMAC7.html)
EP (1) EP3924336A1 (cg-RX-API-DMAC7.html)
JP (1) JP7476216B2 (cg-RX-API-DMAC7.html)
KR (1) KR102927636B1 (cg-RX-API-DMAC7.html)
CN (1) CN113710656B (cg-RX-API-DMAC7.html)
AR (1) AR118050A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020223316A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015689A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129492A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002093A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021010611A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192276A1 (cg-RX-API-DMAC7.html)
IL (1) IL285246B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021009694A (cg-RX-API-DMAC7.html)
PE (1) PE20211701A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108792WA (cg-RX-API-DMAC7.html)
TW (1) TWI808305B (cg-RX-API-DMAC7.html)
WO (1) WO2020168143A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7465883B2 (ja) * 2019-02-15 2024-04-11 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとしての置換二環式化合物
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CA3201686A1 (en) 2021-01-14 2022-07-21 Fabiola Terzi Method for treating chronic kidney diseases
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
TW202308629A (zh) 2021-04-28 2023-03-01 法商Enyo製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
IL316542A (en) * 2022-04-29 2024-12-01 Jiangsu Yahong Meditech Co Ltd Pyrimidine compound, method for its preparation, and pharmaceutical use thereof
CN115057996B (zh) * 2022-06-24 2023-06-02 河南工程学院 4CzIPN型多孔有机聚合物的制备方法及其应用
JP2026524534A (ja) * 2023-07-13 2026-07-22 ウエヌイグレックオ・ファーマ 4-クロロ-5-[4-(2,6-ジクロロフェニル)スルホニルピペラジン-1-イル]-1-ベンゾフラン-2-カルボン酸のl-リジン塩及びそのさまざまな形態
EP4743449A1 (en) * 2023-07-13 2026-05-20 ENYO Pharma L-ARGININE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREIN

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
WO1998017276A1 (en) 1996-10-25 1998-04-30 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
JP4383177B2 (ja) 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション hPPAR活性化剤
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
EP1551813A4 (en) 2002-10-10 2007-07-11 Smithkline Beecham Corp CHEMICAL COMPOUNDS
AU2003290796A1 (en) 2002-11-14 2004-06-15 The Scripps Research Institute Non-steroidal fxr agonists
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
AU2006235115C1 (en) 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
ATE526318T1 (de) 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
WO2008011130A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
WO2008094556A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
BRPI0812851A2 (pt) 2007-07-02 2014-09-30 Glaxosmithkline Llc Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010058318A1 (en) 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
AU2010272523A1 (en) 2009-07-15 2012-02-02 Merck Serono S.A. Tetrazole derivatives
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
JP6099753B2 (ja) 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
WO2014071247A1 (en) 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors
TW201437200A (zh) 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
EP3019196B1 (en) 2013-07-09 2018-06-06 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
WO2015172747A1 (en) 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
JP6564406B2 (ja) 2014-06-19 2019-08-21 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カゼインキナーゼ1デルタ/イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
US10208573B2 (en) 2014-09-10 2019-02-19 Halliburton Energy Services, Inc. Perforating gun with integrated retaining system
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
SG11201704340VA (en) 2014-12-18 2017-07-28 Novartis Ag Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
EP3350165B1 (en) 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN108602811B (zh) 2016-02-01 2021-11-16 轩竹生物科技有限公司 Fxr受体激动剂
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
SI3419624T1 (sl) 2016-02-22 2021-05-31 Novartis Ag Postopki za uporabo agonistov FXR
LT3419625T (lt) 2016-02-22 2021-07-26 Novartis Ag Fxr agonistų panaudojimo būdai
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途
DK3596053T3 (da) 2017-03-15 2023-09-25 Organovo Inc Farnesoid-x-receptoragonister og anvendelser deraf
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
AU2018236275B2 (en) 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
US20200131132A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170165A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN113613649A (zh) * 2019-01-28 2021-11-05 弗拉特利发现实验室有限责任公司 用于治疗囊肿状纤维化的化合物及其治疗方法
US12319676B2 (en) * 2019-02-15 2025-06-03 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid X receptor modulators
JP7588289B2 (ja) 2019-02-15 2024-11-22 ニュートリエン・エージー・ソリューションズ・(カナダ)・インコーポレイテッド 植物の健康を増進するプロトポルフィリンix誘導体及びその使用
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀

Similar Documents

Publication Publication Date Title
RU2014119250A (ru) Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака и иммунных и аутоиммунных заболеваний
JP7860103B2 (ja) 複素環式スピロ化合物及びその使用方法
DK2994467T3 (en) ARYLCHINAZOLIN
CA3120791A1 (en) Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
JP2019512505A5 (cg-RX-API-DMAC7.html)
BRPI1012159B1 (pt) Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
ES2663609T3 (es) Imidazopiridazinas amino-sustituidas
ES2747909T3 (es) Inhibidores duales de quinasas ITK y JAK3 de 3,5-(no)sustituida-1H-pirrolo[2,3-b]piridina, 1H-pirazolo[3,4-b]piridina y 5H-pirrolo[2,3-b]pirazina
JP2019510798A5 (cg-RX-API-DMAC7.html)
JP7628089B2 (ja) 三環式化合物およびそれらの用途
WO2017214458A4 (en) Anti-cd98 antibodies and antibody drug conjugates
JP2015537017A5 (cg-RX-API-DMAC7.html)
JP2022542396A5 (cg-RX-API-DMAC7.html)
RU2012119488A (ru) Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором
JP2014530238A5 (cg-RX-API-DMAC7.html)
CN105732637B (zh) 杂芳化合物及其在药物中的应用
JP2018505903A5 (cg-RX-API-DMAC7.html)
RS56720B1 (sr) Jedinjenja i kompozicije za lečenje parazitskih oboljenja
WO2011146313A1 (en) Pyrazolopyrimidine compounds for the treatment of cancer
WO2010138652A4 (en) Methods for treating kaposi sarcoma
JP2021501805A5 (cg-RX-API-DMAC7.html)
CA2884766A1 (en) Serine/threonine kinase inhibitors
CN116507337A (zh) Atr抑制剂及其用途
IL294078A (en) Combinations
BR112012011147A2 (pt) Composto, composição farmacêutica e uso de um composto.